Regen Biopharma awarded USPTO patent for NR2F6-silenced cord blood killer cell cancer therapy

Regen BioPharma Inc

USPTO issued Patent No. 11,141,471 on Oct 12, 2021, covering universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells.
Invention targets NR2F6 silencing or gene editing in cord blood cells to produce potentiated killer cells for anticancer therapy.
Patent includes compositions of matter, cells, and treatment protocols for inducing anticancer immune responses.
Allogeneic cord blood killer cells are administered to initiate antitumor immune responses, first allogeneic then endogenous.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.